About this episode

This episode explores the challenges of pain management and the potential of non-opioid regenerative therapies.

In this episode of Denatured, you’ll hear from Lance Alstodt, chairman and CEO at Biorestorative Therapies, and Paul Mieyal, chief business officer at South Rampart Pharma. We explore why pain has remained such a difficult therapeutic area to tackle and one of the biggest unmet needs today, and how non-opioid mechanisms to regenerative therapies could reshape the future of treatment. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Lance Alstodt , Chairman & CEO, BioRestorative Therapies Paul Mieyal, Chief Business Officer, South Rampart Pharma Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

People in this episode

Host: Jennifer C. Smith-Parker

Guests: Lance Alstodt, Paul Mieyal

Topics covered

• pain relief
• opioid alternatives
• regenerative therapies
• therapeutic challenges
• healthcare innovation

Keywords

• pain relief
• opioid alternatives
• regenerative therapies
• therapeutic area
• healthcare

Mentioned in this episode

Organizations: Biorestorative Therapies, South Rampart Pharma

More episodes of BioSpace

• Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup · July 15, 2026 · 21 min
• Bonus: Q2 2026 Job Market Update · July 14, 2026 · 9 min
• From sequence to scale: Gene editing’s new era in biologics manufacturing · July 10, 2026 · 21 min
• Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil · July 8, 2026 · 17 min
• Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water · July 1, 2026 · 23 min
• The Golden Triangle and the gaps: Rethinking UK biotech · June 25, 2026 · 20 min

Explore listener stats, chart rankings, contacts and more on the BioSpace podcast page.